Markets in Trouble

A broker monitors a screen displaying live stock quotes on the floor of a trading firm in Mumbai May 23, 2013. REUTERS/Vivek Prakash

Foreign investors still buy stocks

FIIs extended their record net purchases of Indian stocks to a 26th consecutive sessions on Thursday, despite sharp share falls sparked by worries the Fed would unwind its monetary stimulus earlier than expected.  Full Article | Track BSE indices 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Jet-Etihad Deal

Jet-Etihad Deal

Jet Airways shareholders approve Etihad deal.  Full Article 

Tata Steel Shines

Tata Steel Shines

Tata Steel surges; Q4 operating profit beats f'cast.  Full Article 

RBI's May Review

RBI's May Review

Subbarao overrules panel view on rate action in May.  Full Article 

Abe's Agenda

Abe's Agenda

Special Report - The deeper agenda behind "Abenomics".  Full Article 

Bernanke Impact

Bernanke Impact

U.S. Fed enters delicate new phase of communication  Full Article | Related Story 

Revenge of Markets

Revenge of Markets

For months, markets have been dancing to central bankers' tune, but that may now be changing, writes James Saft.  Full Article 

Goldman Safeguards

Goldman Safeguards

Goldman unveils checks on conflicts in bid to fix image.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Cipla to buy control of S.Africa's Cipla Medpro

Related Topics

Stocks

   
Track BSE Sectoral Indices

Track Markets: BSE Sectoral Indices

Track and analyse performance of all BSE sectoral indices and other global indices on a single page.   Full Coverage 

JOHANNESBURG | Wed Nov 21, 2012 3:18pm IST

JOHANNESBURG (Reuters) - Indian drugs maker Cipla Limited (CIPL.NS) has offered to buy a about a 51 percent stake in South Africa's Cipla Medpro (CMPJ.J), to strengthen its position in the fast-growing African drugs market.

The Indian firm has offered 8.55 rand per share, Cipla Medpro said in a statement on Wednesday. The price represents an 11 percent premium on Cipla Medpro's closing share price on Tuesday.

Shares of Cipla Medpro, South Africa's No.3 drug maker, surged 8.58 percent to 8.35 rand on the news.

Cipla supplies the bulk of Cipla Medpro's drugs through a longstanding supply agreement. However, the two have never had a capital alliance.

The agreement was spearheaded by Cipla Medpro's founder and former chief executive, Jerome Smith, who quit last month following charges of "gross misconduct" for approving pay rises and bonsues for himself with board approval.

There had been some speculation in the market that Smith's departure could impact Cipla Medpro's relationship with the Indian company. (Reporting by Tiisetso Motsoeneng; editing by David Dolan)
Business
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.